| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | ISWI; SNF2H; hISWI; hSNF2H; WCRF135 |
| Entrez GeneID | 8467 |
| WB Predicted band size | Calculated MW: 122 kDa; Observed MW: 122 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human SNF2H |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于SMARCA5抗体的参考文献示例(注：以下内容为示例性虚构，实际文献需通过学术数据库检索确认)：
---
1. **标题**: "SMARCA5 regulates chromatin accessibility and DNA repair in mammalian cells"
**作者**: Zhang, L., et al.
**摘要**: 本研究利用SMARCA5特异性抗体进行ChIP-seq分析，揭示SMARTA5在维持染色质开放状态和促进DNA损伤修复中的关键作用，其缺失导致基因组不稳定性增加。
2. **标题**: "Epigenetic dysregulation of SMARCA5 in hepatocellular carcinoma"
**作者**: Tanaka, H., et al.
**摘要**: 通过Western blot和免疫组化(使用SMARCA5抗体)，研究发现肝癌组织中SMARCA5蛋白表达显著下调，且与患者不良预后相关，提示其作为肿瘤抑制因子的潜力。
3. **标题**: "SMARCA5 interacts with pluripotency factors in embryonic stem cells"
**作者**: Gupta, R., et al.
**摘要**: 利用SMARCA5抗体进行免疫共沉淀实验，证实SMARCA5与OCT4/SOX2复合物相互作用，调控胚胎干细胞多能性相关基因的染色质重塑过程。
4. **标题**: "Targeting SMARCA5 in acute myeloid leukemia therapy"
**作者**: Müller, P., et al.
**摘要**: 通过shRNA敲低和SMARCA5抗体检测蛋白水平，研究发现SMARCA5抑制可阻断白血病细胞增殖，为靶向染色质重塑复合物的治疗策略提供依据。
---
建议通过PubMed或Google Scholar以“SMARCA5 antibody”及“ChIP/Western blot/immunoprecipitation”为关键词检索真实文献。
The SMARCA5 antibody targets the SMARCA5 protein, also known as SNF2H or ISWI, a key component of the ATP-dependent chromatin remodeling SWI/SNF complex. SMARCA5 belongs to the ISWI (imitation switch) subfamily of chromatin remodelers and plays a critical role in regulating nucleosome positioning, gene expression, DNA repair, and replication. It functions as an ATPase, utilizing energy to reposition or restructure nucleosomes, thereby modulating chromatin accessibility for transcriptional machinery. SMARCA5 interacts with other chromatin modifiers and is essential for cellular processes like differentiation, proliferation, and genome stability.
Antibodies against SMARCA5 are widely used in research to study its expression, localization, and interaction partners in various biological contexts. They are employed in techniques such as Western blotting, immunoprecipitation (IP), chromatin immunoprecipitation (ChIP), and immunofluorescence (IF). These antibodies help elucidate SMARCA5's involvement in diseases, particularly cancer, where dysregulation of chromatin remodeling is common. For instance, altered SMARCA5 expression has been linked to tumor progression, chemotherapy resistance, and epigenetic abnormalities.
High-quality SMARCA5 antibodies are rigorously validated for specificity and sensitivity, often using knockout cell lines or siRNA knockdown controls. Researchers rely on these tools to explore SMARCA5's role in epigenetic regulation and its potential as a therapeutic target. Commercial antibodies are typically raised in rabbits or mice, with options targeting specific epitopes or post-translational modifications, enabling precise investigation of SMARCA5's functional diversity.
×
